source
- Novo ordered to face CagriSema fraud claims from shareholders: New Jersey courtShareholders allege that Novo Nordisk withheld information about crucial protocol changes in a Phase 3 study of the weight loss drug CagriSema, which led investors to buy company shares “at artific…BioSpace · 10h ago↗ source
- ‘Low tech’ chemotherapy nanoparticles show promise for deadly brain tumor recurrenceA standard chemotherapy drug loaded in nanoparticles has been able to penetrate the blood-brain barrier when administered shortly after resection of the tumor, new research has suggested.Fierce Biotech · 11h ago↗ source
- Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, moreThe FDA published briefing documents ahead of advisory committee meetings for therapies from Capricor Therapeutics and Replimune indicate an uphill battle for the biotechs; GSK and AstraZeneca outl…